Table 1.
List of dacomitinib trials in this review
| ARCHER | NCT number | Description | References |
|---|---|---|---|
| Single-arm Phase I | |||
| 1001 | 00225121 | US Phase I trial | 18 |
| 1003 | 00553254 | South Korea Phase I trial | 20 |
| 1005 | 00783328 | Japan Phase I trial | 19 |
| Single-arm Phase II | |||
| 1002 | 00548093 | US Phase II trial, KRAS WT | 21 |
| 1017 | 00818441 | Single-arm first-line treatment of never-smoker/light former smoker or in EGFR-mutant NSCLC patients | 28 |
| Randomized Phase II | |||
| 1028 | 00769067 | Randomized Phase II dacomitinib versus erlotinib as second-line treatment in unselected NSCLC | 26 |
| Randomized Phase III | |||
| 1009 | 01360554 | Randomized dacomitinib versus erlotinib in second-line treatment of unselected NSCLC | 27 |
| BR-26 | 01000025 | Randomized dacomitinib versus placebo in third-line or beyond treatment of unselected NSCLC | 28 |
| 1050 | 01774721 | Randomized dacomitinib versus erlotinib as first-line treatment of EGFR-mutant (exon 19 deletion or L858R) NSCLC | 29 |
Abbreviations: WT, wild type; NSCLC, non-small-cell lung cancer.